Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Friday morning. The firm issued a sell rating on the stock.

Syros Pharmaceuticals Stock Down 41.4 %

Shares of Syros Pharmaceuticals stock opened at $0.06 on Friday. Syros Pharmaceuticals has a twelve month low of $0.06 and a twelve month high of $6.93. The company has a 50-day simple moving average of $0.16 and a two-hundred day simple moving average of $0.85. The stock has a market capitalization of $1.65 million, a price-to-earnings ratio of -0.02 and a beta of 1.31.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Two Sigma Securities LLC acquired a new position in shares of Syros Pharmaceuticals in the 4th quarter valued at approximately $25,000. Finally, Exome Asset Management LLC raised its position in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after buying an additional 139,400 shares in the last quarter. 91.47% of the stock is currently owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.